-- RBCキャピタル・マーケッツは、サウジアラビア国営石油大手サウジアラムコ(SASE:2222)の第1四半期決算発表を5月に控え、同社のモデルを更新した。 「最新の市場データを反映させた結果、上流部門の生産量予測を下方修正しました。4月と5月は操業停止が継続し、第3四半期にはほぼ通常レベルに戻ると予測しています。上流部門のコストは季節的な要因で前期比で低下し、2026年第1四半期の収益にプラスに働くでしょう。下流部門の収益は、精製マージンの上昇による恩恵を受けると予想されます」とアナリストは火曜日に述べ、調査会社による商品価格の上方修正予測も考慮に入れていることを付け加えた。 そのため、RBCは2026年第1四半期の調整後グループ純利益を302億ドルから320億ドルに引き上げ、2027年および2028年の通期EPS予想も上方修正しました。 同社株のレーティングは引き続き「セクター・パフォーム」で、目標株価は34サウジアラビア・リヤルで据え置きです。
Related Articles
Research Alert: Gsk Q1 Beat As Specialty Medicines Remains Strong, Reiterates 2026 Outlook
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GSK delivered a Q1 2026 beat with sales growing 2% Y/Y (5% CER), led by Specialty Medicines (+10% or +14% CER), particularly oncology with strong Jemperli and Ojjaara uptake, while Vaccines grew 4% CER on record Shingrix sales. Core EPS grew 4% or 9% CER to GBP0.465, ahead of the consensus of GBP0.44, supported by a favorable product mix and cost control that lifted the core operating margin by 1.0%-pt or 1.8%-pts CER. We view the Q1 update positively given the beat and margin expansion, though we are mindful of currency headwinds. GSK reiterated its 2026 guidance for 3%-5% sales growth and 7%-9% core operating profit growth (CER), which is broadly aligned with that of several peers like Sanofi and Roche despite implying slower growth versus 2025. We expect revenue to be supported by key Specialty Medicines products, with GSK targeting the segment to contribute more than 50% of sales by 2031 (Q1 2026: 42%), while recent acquisitions provide a much-needed boost to growth and the drug pipeline, in our view.
Gamuda Unit Bags Nearly MYR6 Billion Project from Sabah State Water Department
Gamuda (KLSE:GAMUDA) unit Upper Padas Power received a Letter of Acceptance worth 5.98 billion ringgit from the Sabah State Water Department for Phase 1 of the Skim Bekalan Air Ulu Padas.The project forms a bolt-on development linked to the Ulu Padas Hydroelectric Project and is designed to strengthen water supply for Sabah's west coast, according to a Wednesday Malaysian bourse filing.Phase 1 involves the construction of a 350 million litres per day water treatment plant in Beaufort, along with about 200km of pipelines stretching from Sipitang to Kota Kinabalu.The project marks a key infrastructure expansion alongside its hydroelectric development in Sabah, Malaysia, the company said.
Aker Solutions to Develop Framed Modules Components for Rolls-Royce SMR
Aker Solutions (AKSO.OL) secured a deal to develop non-nuclear parts of framed modules for Rolls-Royce (RR.L) unit Rolls-Royce SMR, according to a Wednesday release.Under a memorandum of understanding, the Norwegian energy-focused engineering group will work with Rolls-Royce SMR to define the design and scope, and modularization approach for customer projects in the UK and other countries, with an initial focus on the UK and the Czech Republic.